Albemarle Corporation $ALB Shares Bought by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP raised its position in Albemarle Corporation (NYSE:ALB) by 53,430.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 10,706 shares of the specialty chemicals company’s stock after purchasing an additional 10,686 shares during the period. Fulcrum Asset Management LLP’s holdings in Albemarle were worth $1,132,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of ALB. Avion Wealth raised its position in Albemarle by 1,790.5% in the 3rd quarter. Avion Wealth now owns 794 shares of the specialty chemicals company’s stock valued at $84,000 after purchasing an additional 752 shares during the last quarter. University of Texas Texas AM Investment Management Co. grew its position in Albemarle by 3,416.3% during the 3rd quarter. University of Texas Texas AM Investment Management Co. now owns 9,951 shares of the specialty chemicals company’s stock worth $1,053,000 after purchasing an additional 9,668 shares during the last quarter. Brighton Jones LLC grew its position in Albemarle by 101.2% during the 3rd quarter. Brighton Jones LLC now owns 9,560 shares of the specialty chemicals company’s stock worth $1,011,000 after purchasing an additional 4,809 shares during the last quarter. Candriam S.C.A. grew its position in Albemarle by 7,328.6% during the 3rd quarter. Candriam S.C.A. now owns 410,874 shares of the specialty chemicals company’s stock worth $43,462,000 after purchasing an additional 405,343 shares during the last quarter. Finally, Ethic Inc. increased its stake in Albemarle by 233.0% in the third quarter. Ethic Inc. now owns 71,694 shares of the specialty chemicals company’s stock valued at $7,584,000 after purchasing an additional 50,167 shares during the period. 92.87% of the stock is owned by institutional investors and hedge funds.

Albemarle Trading Up 1.3%

Shares of Albemarle stock opened at $96.14 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.34 and a quick ratio of 1.57. Albemarle Corporation has a 1 year low of $89.77 and a 1 year high of $221.00. The company has a market capitalization of $11.35 billion, a P/E ratio of 23.22, a P/E/G ratio of 0.59 and a beta of 1.34. The business has a 50 day moving average price of $105.23 and a 200 day moving average price of $146.54.

Albemarle (NYSE:ALB) last posted its earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.52 billion. Albemarle had a return on equity of 14.91% and a net margin of 10.40%. Albemarle’s revenue was up 18.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.19) EPS. Sell-side analysts anticipate that Albemarle Corporation will post 10.75 EPS for the current fiscal year.

Albemarle Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, December 18th will be given a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Friday, December 18th. Albemarle’s dividend payout ratio is currently 39.61%.

Wall Street Analysts Forecast Growth

ALB has been the subject of a number of research reports. Royal Bank Of Canada reduced their target price on shares of Albemarle from $129.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, November 6th. Morgan Stanley lowered their price target on Albemarle from $161.00 to $105.00 and set an “equal weight” rating on the stock in a report on Monday. JPMorgan Chase & Co. dropped their price target on Albemarle from $160.00 to $140.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 25th. Mizuho upgraded Albemarle from a “neutral” rating to an “outperform” rating and set a $130.00 price target on the stock in a research report on Wednesday, October 14th. Finally, Barclays reduced their price objective on Albemarle from $109.00 to $95.00 and set an “equal weight” rating for the company in a research note on Friday, November 6th. Fifteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $174.05.

Recent Albemarle Headlines

These are some of the ALB headlines that stood out recently:

• Positive Sentiment: Citigroup raised its price target for ALB, signaling greater potential upside in its valuation, though the reported headline did not give the new target. Read more about Citigroup’s price target increase
• Negative Sentiment: Scotiabank cut its EPS forecasts to $10.36 for FY2026 from $11.64 and to $9.98 for FY2027 from $14.15. The lower projections may weigh on sentiment, although the bank maintained its “Sector Outperform” rating and $165 price target. Read more about analyst estimates for Albemarle
• Negative Sentiment: UBS Group and Morgan Stanley each cut their price targets for Albemarle, adding to concerns about the stock’s near-term upside. The reports did not specify the revised targets in the headlines. Read more about UBS’s price target cut Read more about Morgan Stanley’s price target cut

About Albemarle

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals. The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum. Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.